BlackRock Discloses Passive Stake in Cue Biopharma
Ticker: CUE · Form: SC 13G · Filed: Jan 31, 2024 · CIK: 1645460
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock just revealed a stake in Cue Biopharma, signaling institutional confidence.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 31, 2024, that it holds a significant stake in Cue Biopharma, Inc. as of December 31, 2023. This filing indicates BlackRock's passive investment in the pharmaceutical company's common stock. For investors, this means a large institutional player sees value in Cue Biopharma, potentially signaling stability or future growth prospects for the stock.
Why It Matters
When a giant like BlackRock invests, it often lends credibility to a company, which can positively influence other investors' perceptions and potentially the stock price.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces perceived risk for the underlying company.
Analyst Insight
A smart investor would view BlackRock's passive stake as a positive signal, potentially prompting further research into Cue Biopharma's fundamentals and future prospects, especially given the institutional validation.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Cue Biopharma, Inc. (company) — the subject company whose common stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 31, 2024 (date) — the filing date of the SC 13G
Forward-Looking Statements
- Other institutional investors may increase their positions in Cue Biopharma, Inc. (Cue Biopharma, Inc.) — medium confidence, target: Within the next 6 months
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically filed under Rule 13d-1(b) as indicated by the 'X' in the appropriate box.
Who is the 'reporting person' in this filing?
The reporting person is BlackRock, Inc., identified by CIK 0001364742 and located at 50 Hudson Yards, New York, NY.
What is the 'subject company' of this filing?
The subject company is Cue Biopharma, Inc., identified by CIK 0001645460, with its business address at 40 Guest Street, Boston, MA.
What class of securities is being reported?
The class of securities being reported is 'Common Stock' of Cue Biopharma, Inc.
What is the CUSIP number for the securities mentioned?
The CUSIP number for the Common Stock of Cue Biopharma, Inc. is 22978P106.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 31, 2024 regarding Cue Biopharma, Inc. (CUE).